Spero Therapeutics, Inc. (SPRO)

Market Cap	70.45M
Revenue (ttm)	110.98M
Net Income (ttm)	23.40M
Shares Out	53.99M
EPS (ttm)	0.44
PE Ratio	2.97
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	34,294
Open	1.280
Previous Close	1.280
Day's Range	1.280 - 1.310
52-Week Range	0.990 - 1.890
Beta	0.64
Analysts	Strong Buy
Price Target	7.00 (+436.4%)
Earnings Date	Aug 8, 2024

About SPRO

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant e...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 2, 2017
• Employees: 46
• Stock Exchange: NASDAQ
• Ticker Symbol: SPRO

Analyst Forecast

According to 2 analysts, the average rating for SPRO stock is "Strong Buy." The 12-month stock price forecast is $7.0, which is an increase of 436.40% from the latest price.

Price Target

$7.0

(436.40% upside)

Analyst Consensus: Strong Buy